Alterity Commences Mid-Stage Neurodegenerative Disorder Study
July 06, 2022 at 11:37 AM EDT
Alterity Therapeutics (NASDAQ: ATHE) doses first subject in its Phase 2 clinical trial of lead candidate ATH434 in Multiple System ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.